Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 16/20 | 0.38 |
| ▸ | HTR2C | P28335 | 16/20 | 0.38 |
| ▸ | HTR2B | P41595 | 16/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8983628 | 0.72 | SLC6A2 (0.49) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL5797267 | 0.72 | HTR2C (0.48) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL8916947 | 0.71 | ALDH1A1 (0.40) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2892940 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL16235859 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL224088 | 0.71 | TDP1 (0.32) | TDP1 | |
| SCHEMBL8692588 | 0.71 | TDP1 (0.35) | TDP1 | |
| SCHEMBL5330905 | 0.69 | SLC6A2 (0.47) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL6180006 | 0.69 | ALDH1A1 (0.47) | KDM4EALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL10877701 | 0.69 | ALDH1A1 (0.47) | KDM4EALDH1A1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441175-B1 | 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| US-6252077-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6245768-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6031097-A | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| US-5932729-A | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1998029410-A1 | 1-(N'-(ARYLALKYLAMINOALKYL)) AMINOISOINDOLES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5744472-A | NEUROLEPTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| US-5656632-A | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5602168-A | USEFUL IN TREATING VARIOUS NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996039403-A1 | 1-(N'-(ARYLALKYLAMINOALKYL)) AMINOISOINDOLES AS DOPAMINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | DRD2, DRD1, CHRNA5 | KDM4E 3234/4885ALDH1A1 458/4885HTR2A 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.